Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term rt [Radiotherapy]. Found 30 abstracts

no pagination
Morrow M, Freedman G. A clinical oncology perspective on the use of breast MR. Magnetic Resonance Imaging Clinics of North America. 2007 Aug;14(3):363-78.
Chen X, Arciero CA, Godwin AK. BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance. Expert Review of Anticancer Therapy. 2006 Feb;6(2):187-96.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer. American Journal of Clinical Oncology. 2006 Oct;29(5):458-62.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer N. Rectal cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2005 Jul;3(4):492-508.
Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. International Journal of Radiation Oncology, Biology, Physics. 2005 Jul 15;62(4):956-64.
Mu Z, Hachem P, Pollack A. Antisense Bcl-2 sensitizes prostate cancer cells to radiation. The Prostate. 2005 Dec;65(4):331-40.
Paskalev K, Feigenberg S, Jacob R, McNeeley S, Horwitz E, Price R, Ma C, Pollack A. Target localization for post-prostatectomy patients using CT and ultrasound image guidance. Journal of Applied Clinical Medical Physics. 2005 Jan;6(4):40-9.
Rogers B. Looking at lymphoma and leukemia. Nursing. 2005 Jul;35(7):56-63; quiz 63-4.
Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.[see comment]. Cancer Research. 2004 Sep;64(17):6200-6.
Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Seminars in Nuclear Medicine. 2004 Jan;34(1 Suppl 1):4-9.
Borghaei H, Wallace SG, Schilder RJ. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Clinical Lymphoma. 2004 Oct;5 Suppl 1:S16-21.
Chen L, Price RA, Wang L, Li J, Qin L, McNeeley S, Ma CM, Freedman GM, Pollack A. MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT. International Journal of Radiation Oncology, Biology, Physics. 2004 Oct;60(2):636-47.
Horwitz EM, Feigenberg SJ, Uzzo RG. The treatment of non-metastatic prostate cancer with external beam radiation therapy. Minerva Urologica e Nefrologica. 2004 Jun;56(2):173-88.
Kramer NM, Horwitz EM, Uzzo RG, Hanlon AL, Hanks GE. Matched-cohort analysis of patients with prostate cancer followed with observation or treated with three-dimensional conformal radiation therapy. BJU international. 2004 Jul;94(1):59-62.
Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M, Shipley WU, Hanks GE, Sandler HM. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group trial 92-02. Journal of Clinical Oncology. 2004 Jun;22(11):2133-40.
Wang L, Jacob R, Chen L, Ma C, Movsas B, Feigenberg S, Konski A. Stereotactic IMRT for prostate cancer: setup accuracy of a new stereotactic body localization system. Journal of Applied Clinical Medical Physics. 2004 Jan;5(2):18-28.
Wang L, Movsas B, Jacob R, Fourkal E, Chen L, Price R, Feigenberg S, Konski A, Pollack A, Ma C. Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT. Journal of Applied Clinical Medical Physics. 2004 Jan;5(2):29-41.
Feigenberg SJ, Wolk KL, Yang CH, Morris CG, Zlotecki RA. Celecoxib to decrease urinary retention associated with prostate brachytherapy. Brachytherapy. 2003 Jan;2(2):103-7.
Fourkal E, Li JS, Xiong W, Nahum A, Ma CM. Intensity modulated radiation therapy using laser-accelerated protons: a Monte Carlo dosimetric study. Physics in Medicine and Biology. 2003 Dec;48(24):3977-4000.
Langer C, Damsker J, Ridge A. Reirradiation: exploring new territory in the therapy of recurrent head and neck cancer. Clinical Advances in Hematology & Oncology. 2003 Jul;1(7):424-9, 440.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term rt [Radiotherapy]

rt [Radiotherapy] Prostatic Neoplasms Male mt [Methods] Conformal Radiotherapy tu [Therapeutic Use] Human di [Diagnosis] Computer-Assisted Radiotherapy Planning Radiotherapy Dosage ae [Adverse Effects] dt [Drug Therapy] Aged Treatment Outcome 80 and over Aged Survival Analysis pa [Pathology] X-Ray Computed Tomography Middle Aged Non-US Gov't Research Support Breast Neoplasms Combined Modality Therapy ra [Radiography] 0 (Antineoplastic Combined Chemotherapy Protocols) Neoplasm Staging Yttrium Radioisotopes Antineoplastic Combined Chemotherapy Protocols Use] su [Surgery] Reproducibility of Results Radioimmunotherapy im [Immunology] Female tu [Therapeutic Sensitivity and Specificity pd [Pharmacology] Prostate-Specific Antigen NIH Research Support-Extramural Non-Hodgkin Lymphoma bi [Biosynthesis] Tumor Cell Line Brachytherapy Immobilization is [Instrumentation] Monoclonal Antibodies me [Metabolism] Radiosurgery Equipment Design bl [Blood] mo [Mortality] aa [Analogs & Derivatives] 0 (Yttrium Radioisotopes) Local Neoplasm Recurrence Magnetic Resonance Imaging Radiometry et [Etiology] Three-Dimensional Imaging US Gov't Support-PHS Radiotherapy ge [Genetics] Prognosis US Gov't Support-Non-PHS Non-US Gov't Support Equipment Failure Analysis Risk Factors Comparative Study Urinary Incontinence CD20) 0 (Antigens human) 0 (TP53 protein 2-diamine (N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1 Neoplasm Invasiveness Radiation Tolerance ri [Radionuclide Imaging] Cohort Studies follow-up studies Ultrasonography Xenograft Model Antitumor Assays Ovarian Neoplasms Monte-Carlo Method Apoptosis Outcome Assessment (Health Care) 58-05-9 (Leucovorin) Radiographic Image Enhancement 0 (Proto-Oncogene Proteins c-bcl-2) BRCA1 Protein High-Energy Radiotherapy Monoclonal) 0 (Antibodies SCID Mice 0 (Radiation-Sensitizing Agents) Segmental Mastectomy Lymphoma 0 (Immunotoxins) Antisense) 0 (DNA Lung Neoplasms Flow Cytometry 0 (Organoplatinum Compounds) Comparative study Ki-67 Antigen 0 (Folfox protocol) Adjuvant Chemotherapy [Instrumentation] 0 (Iodine Radioisotopes) Impotence Adult Computer-Assisted Radiographic Image Interpretation Antisense DNA erbB-2) EC 2-7-1-112 (Receptor Adjuvant Radiotherapy Tissue Distribution Mice 0 (IFL protocol) 0 (Cyclin-Dependent Kinase Inhibitor p21) Camptothecin Foreign-Body Reaction Questionnaires Follow-up studies Imaging Phantoms Medical Oncology 0 (Immunoglobulin Variable Region) Leucovorin pk [Pharmacokinetics] re [Radiation Effects] Isothiocyanates Radiation-Sensitizing Agents EC 3-4-22 (caspase 7) Clinical Trials mt st [Standards] Pentetic Acid Body Burden Urinary Retention mt [Method] Quality of Life Proportional Hazards Models CD20 Antigens Rectum Liver Neoplasms ai [Antagonists & Inhibitors] Prostatectomy Safety Karnofsky Performance Status ph [Physiology] Proto-Oncogene Proteins c-bcl-2 Statistical Models Nude Mice Cyclin-Dependent Kinase Inhibitor p21 67-43-6 (Pentetic Acid) Biological Models 51-21-8 (Fluorouracil) Prospective Studies
Last updated on Wednesday, February 05, 2020